Columbus Macro LLC Has $2.32 Million Position in AstraZeneca PLC $AZN

Columbus Macro LLC grew its holdings in AstraZeneca PLC (NASDAQ:AZN) by 1.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 33,125 shares of the company’s stock after purchasing an additional 350 shares during the quarter. Columbus Macro LLC’s holdings in AstraZeneca were worth $2,315,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Brighton Jones LLC grew its position in AstraZeneca by 93.2% during the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after buying an additional 2,789 shares in the last quarter. Capital Investment Advisors LLC acquired a new stake in AstraZeneca during the first quarter worth about $213,000. Farther Finance Advisors LLC grew its position in AstraZeneca by 13.1% during the first quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company’s stock worth $442,000 after buying an additional 706 shares in the last quarter. Wealthcare Advisory Partners LLC grew its position in AstraZeneca by 12.9% during the first quarter. Wealthcare Advisory Partners LLC now owns 3,723 shares of the company’s stock worth $274,000 after buying an additional 424 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in AstraZeneca by 43.3% during the first quarter. GAMMA Investing LLC now owns 7,878 shares of the company’s stock worth $579,000 after buying an additional 2,380 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Down 0.6%

NASDAQ AZN opened at $85.38 on Thursday. The company has a current ratio of 0.86, a quick ratio of 0.67 and a debt-to-equity ratio of 0.55. The stock’s 50 day moving average is $78.73 and its two-hundred day moving average is $73.30. The company has a market capitalization of $264.80 billion, a price-to-earnings ratio of 32.10, a PEG ratio of 1.58 and a beta of 0.36. AstraZeneca PLC has a 1-year low of $61.24 and a 1-year high of $86.57.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. The company had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The company’s quarterly revenue was up 16.1% on a year-over-year basis. During the same period in the previous year, the business earned $1.24 earnings per share. Equities analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were issued a dividend of $0.505 per share. This represents a yield of 200.0%. The ex-dividend date of this dividend was Friday, August 8th. AstraZeneca’s payout ratio is presently 37.97%.

Analyst Ratings Changes

A number of research firms recently weighed in on AZN. Berenberg Bank set a $97.00 target price on AstraZeneca in a research report on Wednesday, July 9th. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of $86.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.